Carmen Betancourt
General Counsel at CIDARA THERAPEUTICS, INC.
Profile
Carmen Betancourt is currently the Executive VP-Regulatory Affairs & Quality at Cidara Therapeutics, Inc. since 2014.
Prior to this, Carmen was the Managing Member at Golden Gate Bioventures LLC starting in 2013.
Carmen's former positions include being the Senior Director-Regulatory Affairs at Coulter Pharmaceuticals, Inc. from 1997 to 2000, Manager-Regulatory Affairs at Genentech, Inc. from 1992 to 1997, Vice President-Regulatory Affairs at Titan Pharmaceuticals, Inc. from 2001 to 2002, Senior Vice President-Regulatory Affairs at VaxGen, Inc. from 2002 to 2006, Senior Vice President-Regulatory Affairs at Humanigen, Inc. from 2006 to 2007, Vice President-Regulatory Affairs at Cerexa, Inc. from 2008 to 2009, and Vice President-Regulatory Affairs at Sangart, Inc. from 2013 to 2014.
Carmen's education includes an MBA from Golden Gate University in 1991 and an undergraduate degree from the University of California, Davis in 1977.
Carmen Betancourt active positions
| Companies | Position | Start |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | General Counsel | 2013-12-31 |
| Golden Gate Bioventures LLC | Corporate Officer/Principal | 2013-11-30 |
Former positions of Carmen Betancourt
| Companies | Position | End |
|---|---|---|
Sangart, Inc.
 Sangart, Inc. Pharmaceuticals: MajorHealth Technology Sangart, Inc. developed blood transfusion solutions. It is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. The company was founded in 1998 and was headquartered in San Diego, CA. | General Counsel | 2013-12-31 |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | General Counsel | 2008-12-31 |
| HUMANIGEN, INC. | General Counsel | 2006-12-31 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | General Counsel | 2005-12-31 |
| TITAN PHARMACEUTICALS, INC. | General Counsel | 2001-12-31 |
Training of Carmen Betancourt
| Golden Gate University | Masters Business Admin |
| University of California, Davis | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Sangart, Inc.
Sangart, Inc. Pharmaceuticals: MajorHealth Technology Sangart, Inc. developed blood transfusion solutions. It is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. The company was founded in 1998 and was headquartered in San Diego, CA. | Health Technology |
| Golden Gate Bioventures LLC |
- Stock Market
- Insiders
- Carmen Betancourt
